Menu Close

Amgen Inc

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world’s largest independent biotechnology companies, Amgen’s Thousand Oaks staff in 2022 numbered approximately 5,000 (8.5% of total city employment) and included hundreds of scientists, making Amgen the largest employer in Ventura County. As of 2022, Amgen has approximately 24,000 staff in total.

In 2019, the company’s largest selling products were Enbrel (etanercept), a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases, and Neulasta (pegfilgrastim), an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy. Other marketed products include Evenity (romosozumab-aqqg), Otezla (apremilast), Prolia (denosumab), Repatha (evolocumab), and Lumakras (sotorasib).


One Amgen Center Drive
Thousand Oaks CA 91320‐1799

Product Approval Dates

27‐OCT‐2015 Talimogene laherparepvec


Amgen’s approved drugs or therapeutic biologicals include:

  • Aimovig (erenumab-aooe) for migraine headaches
  • Amjevita (adalimumab)
  • Aranesp (darbepoetin alfa) for anemia
  • Blincyto (blinatumomab for the treatment of acute lymphoblastic leukemia)
  • Corlanor (ivabradine)
  • Enbrel (etanercept) for various forms of arthritis
  • Epogen (erythropoietin) for anemia
  • Evenity (romosozumab-aqqg) for osteoporosis
  • Imlygic (talimogene laherparepvec) for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in melanoma recurrent after initial surgery
  • Kanjinti (trastuzumab-anns)
  • Kyprolis (carfilzomib)
  • Lumakras (sotorasib)
  • Mvasi (bevacizumab-awwb)
  • Neulasta (pegfilgrastim) for neutropenia
  • Neupogen (granulocyte colony-stimulating factor) for neutropenia
  • Nplate (romiplostim) for chronic immune thrombocytopenic purpura
  • Otezla (apremilast)
  • Parsabiv (etelcalcetide)
  • Prolia (denosumab) for postmenopausal osteoporosis
  • Repatha (evolocumab)
  • Riabni (rituximab-arrx)
  • Sensipar/Mimpara (cinacalcet for primary and secondary hyperparathyroidism, a mineral metabolism complication common in patients with kidney failure)
  • Tezspire (tezepelumab-ekko)
  • Vectibix (panitumumab for colon cancer)
  • Xgeva (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone in adults with bone metastases from solid tumors)

Products developed and then sold off

  • Kepivance (palifermin for oral mucositis, sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008
  • StemGen (ancestim) for use in combination with filgrastim for mobilizing peripheral hematopoietic stem cells) (sold to Biovitrium, now Swedish Orphan Biovitrum, in December 2008)
  • Kineret (anakinra) for rheumatoid arthritis, exclusively licensed to Biovitrium, now Swedish Orphan Biovitrum, in December 2008


Leave a Reply

Please leave correct email if you want us to contact you

Your email address will not be published. Required fields are marked *